Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine ER in Children and Adolescents With ADHD
CTR20232661Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Yichang Humanwell Pharmaceutical Co., Ltd.. Started Aug 2023; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20232661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232661.